Change - Announcement of Appointment::Appointment of Chief Technology Officer

Issuer & Securities

Issuer/ Manager
BIOSENSORS INTERNATIONAL GROUP, LTD.
Securities
BIOSENSORS INT'L GROUP, LTD. - BMG113251000 - B20

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
28-May-2014 17:44:27
Status
New
Announcement Sub Title
Appointment of Chief Technology Officer
Announcement Reference
SG140528OTHR1K9Z
Submitted By (Co./ Ind. Name)
Ronald H. Ede
Designation
Chief Financial Officer/ Company Secretary
Description (Please provide a detailed description of the event in the box below)
Appointment of Dr Jack Wang as Chief Technology Officer

Additional Details

Date Of Appointment
28/05/2014
Name Of Person
Jack Wang Chicheng
Age
53
Country Of Principal Residence
China
The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)
The Board of Directors having reviewed Dr Wang s qualifications and working experience, approved the appointment of Dr Jack Wang as Chief Technology Officer of the Company.
Whether appointment is executive, and if so, the area of responsibility
The appointment is executive in nature. Dr Wang will be responsible for the Group s research and development and new process technology development.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Technology Officer
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
Nil
Conflict of interests (including any competing business)
Nil
Working experience and occupation(s) during the past 10 years
Dr Jack Wang joined Biosensors in 2001. He was appointed as co-CEO and executive director of Biosensors before became CEO of Biosensors in March 2012. Dr Wang has been involved in Biosensors product development and operating activities, first serving as Vice President for Research & Development, then as Chief Operating Officer, as well as President and CEO of JW Medical System Ltd ( JWMS ).

Prior to joining Biosensors in 2001, Dr Wang was a manager of new product development for Johnson & Johnson (Cordis) and project group leader in stent delivery systems for Guidant Corporation. Dr Wang was granted more than 20 US and European patents in medical devices and technology and has published more than 30 scientific papers on polymer materials and processing.

Dr Wang received his doctorate in polymer science from Case Western Reserve University, Cleveland, Masters Degree in Science in Chemical Engineering from Clarkson University, Potsdam and Bachelor of Science Degree in Chemistry and Chemical Engineering from Tsinghua University, Beijing.
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
Dr Wang owns 300,000 shares and 9,035,111 options of Biosensors
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Nil
Present
JW Medical Systems Limited and JWICU Medical Limited
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of a listed company?
Yes
If Yes, Please provide full details
Dr Wang has been serving as an executive director of the Company since 8 November 2010.